|
مقاله
|
Abstract
|
|
|
Title:
|
The effect of intracameral injection of Bevacizumab on posterior capsular opacification after congenital cataract surgery
|
Author(s):
|
Mohammadreza Talebnejad M.D, Gholamabbas Roustaei M.D, Mansour Rahimi M.D
|
Presentation Type:
|
Poster
|
Subject:
|
Cornea and Anterior Segment
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Mohammad reza Talebnejad
|
Affiliation :(optional)
|
Poostchi Eye Research Center ,Shiraz University of Medical Sciences
|
E mail:
|
talebnejadmr@yahoo.com
|
Phone:
|
07112302830
|
Mobile:
|
09171311993
|
|
|
Purpose:
|
Posterior capsular opacification (PCO) is the most common complication of cataract surgery especially in pediatric age group. Bevacizumab in addition to have antiangiogenesis effect has decreased the proliferation of the fibroblasts and epithelial cells and maybe intracameral injection of bevacizumab after cataract surgery can reduce or postpone the occurrence of PCO.
|
Methods:
|
Four patients were included in the study. Patients underwent phacoaspiration and intraocular lens implantation and one eye of each patient randomly assigned to either receiving intracameral bevacizumab (ICB) 1.25 mg/0.05 ml or BSS as control. Image processing and calculating PCO score were done using an Objective System Capsule Analysis (OSCA).
|
Results:
|
At 2 months, a mean OSCA PCO score of 0.4346 ± 0.2191 and 0.7709 ± 0.5275 were found for the ICB and control group respectively. The values were 0.8782 ± 0.2015 and 1.2291 ± 0.2820 for the ICB and control group respectively. There were no significant difference of the mean OSCA PCO score between the two groups at 2 month and 1 year postoperatively (p = 0.284 and p = 0.089, respectively).
|
Conclusion:
|
Although one year PCO score at the ICB group was less than that of the controls, the difference was not statistically significant.
|
Attachment:
|
444Dr Talebnejad.pptx
|
|